Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01140555 | A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device | terminated | N/A | 2 | Ethicon, Inc.INDUSTRY | 4 | Feb 17, 2011 | clinicaltrials |
| NCT00531778 | NYU Ovarian Cancer Early Detection Program Blood and Genetics | terminated | — | 890 | NYU Langone HealthOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT00653952 |
| CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
| terminated |
| Phase 3 |
| 220 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY |
| 0 |
| Apr 27, 2010 |
| clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer | terminated | Phase 1 | 12 | University of Alabama at BirminghamOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00161226 | A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35 | terminated | — | 44 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00782041 | Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer | terminated | Phase 2 | 11 | SanofiINDUSTRY | 1 | Sep 15, 2009 | clinicaltrials |
| NCT00584207 | Radiofrequency Ablation of Uterine Fibroids | terminated | Early Phase 1 | 15 | University of California, DavisOTHER | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00034138 | A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | terminated | Phase 1 / Phase 2 | 24 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00034372 | Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma | terminated | Phase 2 | 102 | Unither PharmaceuticalsINDUSTRY | 2 | Dec 18, 2007 | clinicaltrials |
| NCT00050375 | Clinical Trial for Ovarian Cancer (OvaRex®) | terminated | Phase 3 | 354 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | terminated | Phase 3 | 847 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | terminated | Phase 2 | 38 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Apr 18, 2007 | clinicaltrials |
| NCT00287482 | Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer. | terminated | N/A | 20 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Feb 12, 2007 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00220532 | Folate and Protection Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 180 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | terminated | Phase 3 | 300 | AGO Study GroupOTHER | 1 | Sep 19, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2011source: clinicaltrials